I am not going to name a competitor in this article. I have written this way before and I will keep writing this way: the useful thing is the pattern, not the storefront. But everything described below is drawn from pages currently live and publicly advertised in Georgia and Tennessee, and I have quoted the language exactly, because paraphrasing marketing copy is how you accidentally make it sound more reasonable than it is.
The July 2026 FDA advisory committee meeting created a strange window. For the first time, there is a detailed federal record of what is and is not known about these substances — and simultaneously, a wave of marketing treating that meeting as a starting gun. Those two things are moving in opposite directions. A patient standing in the middle needs a way to tell them apart.
Four questions do most of the work.
"Which peptides do you offer, by name — and is each one lawful to compound today?"
This is the question that separates a clinical practice from a catalog. Legality is per-substance, and it is not binary across the category. Six peptides were recommended by the committee in July. One was declined. And a great many that are actively advertised — CJC-1295 is the most common — were never on the docket at all, which means the July vote did nothing for them in either direction.
What a good answer sounds like"Here is our list. These are recommended but not yet listed, which means a recommendation is not a rule. This one we don't carry, and here's the reason. That one was never reviewed, so nothing changed for it in July."
"Are peptides legal? Yes."
That two-word answer appears verbatim in the FAQ of more than one clinic marketing to this region. It is not a simplification of a complicated truth. It is a different claim than the truth, and the person writing it either has not read the record or has decided you won't.
Watch also for the blend. A named, pre-formulated combination — sold as a sleep product, a recovery product, a longevity product — fixes the ratio of several active substances before anyone has seen your labs. It also conveniently obscures question one, because the answer becomes a brand name instead of a list of drugs. One such blend advertised near Dalton contains a substance the panel declined, a substance never reviewed, and a substance recommended for an unrelated indication.
"What did the July 2026 committee actually decide — and what did it not decide?"
This is a reading-comprehension test, and it is unusually diagnostic because the correct answer is short and the incorrect answers are all flattering to the seller.
What a good answer sounds like"An advisory committee recommended six of seven for the 503A bulks list. FDA is not bound by it. Rulemaking has not happened. Nothing has been added to any list, and legal commentators expect final action no sooner than late 2027."
"As restricted peptides become legally compoundable again, our members are the first to get access."
Two errors are stacked in that sentence. The first is again. These substances would not be returning to a status they previously held — as FDA's own presenter said at the July hearing, adding them would create legal access for the first time. I know this error intimately, because this website carried it for three months and I corrected it in public rather than editing it quietly.
The second error is first to get access. That is a scarcity promise built on a regulatory event that has not occurred and may not occur on the implied timeline. It converts a patient's uncertainty into a reason to subscribe now.
"Where does this come from, and can I see the per-lot certificate of analysis?"
Here is where the most sophisticated-sounding misdirection in this industry lives, and it is worth slowing down for, because it fools careful people.
You will frequently read some version of: "All peptides are sourced from licensed, FDA-regulated compounding pharmacies, made in the USA in a regulated 503A pharmacy." Every clause in that sentence can be true while the underlying product remains unlawful — because pharmacy licensure and bulk-substance eligibility are two entirely separate questions.
A 503A pharmacy may be fully licensed, inspected, accredited, and beyond reproach in its sterile technique, and still not be permitted to compound from a bulk drug substance that is not eligible under section 503A. The pharmacy's credential says nothing about the substance. Answering a substance question with a pharmacy credential is a change of subject, and it is so common that I suspect most of the people writing it don't realize they're doing it.
There is a second, quieter problem underneath: the active pharmaceutical ingredient itself. Pharmaceutical-grade API for several of these peptides does not exist at meaningful commercial scale. Research-grade material is not a lawful input for a dispensed compounded preparation. Several committee members who voted yes in July explicitly conditioned their support on API sourcing standards and adverse-event reporting — which tells you they saw the same gap.
What a good answer sounds like"Named 503A pharmacy, patient-specific prescription, per-lot certificate of analysis you can see. Here is where the API comes from and here is what we don't yet know about it."
"Every batch undergoes third-party testing for purity, potency, and sterility." — with no pharmacy named, no lot document offered, and no distinction drawn between testing the product and being permitted to make it.
"Who wrote the page I just read, and when was it last updated?"
The cheapest test on this list, and startlingly effective. Regulatory pages go stale silently — there is no error message when a claim expires.
One well-designed Georgia telehealth practice currently markets peptide therapy on a page stamped "Last updated: March 2026." That date sits before the April reclassification and roughly four months before the advisory committee met. Everything on it describing the regulatory landscape is describing a world that no longer exists — and the page is not marked as historical.
An undated page is worse. An undated, unsigned page describing federal drug policy is a page no one has taken responsibility for.
What should worry youNo author. No date. Or a date that predates the events the page is describing.
A fifth question I have started asking.
This one is newer, and I want to be careful with it, because it is a criticism of a structure rather than of anyone's competence.
A membership model increasingly common in this space bundles drug quantity into the subscription — sold as "credits." One Georgia telehealth practice offers 200 credits per month at one tier and 400 at another, with an add-on of 125 credits for $125 per month. The credits are explicitly described as covering the cost of your peptide medications, priced by wholesale cost of the compound.
As pricing, it is genuinely clever: predictable for the patient, predictable for the business. As clinical structure, it creates a quiet pull in one direction. A patient who is paying monthly for 400 credits has an economic reason to use 400 credits. A practice whose revenue is denominated in dispensed quantity has an economic reason not to talk them out of it. Neither party has to be acting in bad faith for the incentive to bend the medicine — that is what makes structural incentives worth naming.
Attorneys writing about telehealth prescribing models after the July vote have flagged this general shape — subscription models where the recurring charge is tied to receiving medication — as an area of regulatory exposure independent of whether the underlying prescribing is sound.
What we do instead: at Limitless you pay for the physician's time, the analysis, and the monitoring. Medication is billed at what it costs. If the right answer is that you need less of something, or none of it, that decision costs the practice nothing. I want the incentive pointed at your outcome, not at your volume.
A sixth question. This one is a federal statute.
I added this one on 2026-08-16, after reading the patient agreement of a telehealth practice that advertises into both Georgia and Tennessee. It is the easiest question on this page to verify yourself, and it takes about thirty seconds.
"Does your patient agreement restrict what I am allowed to say in a review?"
Buried in the terms of a practice currently marketing peptide therapy in this region, past the risk disclosures and the arbitration clause, is this:
"You agree not to publish any content online or in any public space, including but not limited to social media, review websites, or public forums, related to your experience with [the practice] without our prior written approval. This includes both positive and negative reviews."
Read that last sentence again. Not just complaints — praise too, unless it is cleared first. A practice that must approve your compliments before you post them is not managing its reputation. It is manufacturing one.
And it is doing so unlawfully. The Consumer Review Fairness Act, 15 U.S.C. § 45b, was enacted in 2016 for precisely this. A provision in a form contract that prohibits or restricts a customer's ability to review a business is void from the inception of the contract — not voidable, not unenforceable going forward, void from day one. Offering such a form contract is itself a per se unfair or deceptive act under the FTC Act, enforceable by the Federal Trade Commission and by state attorneys general.
This is not a theoretical exposure for medical practices specifically. A federal judge in Washington found that a medical clinic's use of nondisclosure agreements to suppress negative patient reviews violated the CRFA. The clinic argued the agreements served privacy interests. That did not save them.
What a good answer sounds like"No. Nothing in our agreement touches what you say about us. Here is the document — search it yourself."
Any version of "we just ask that you come to us first." Also: an agreement you are asked to sign on a tablet at check-in and are not emailed a copy of.
I want to be clear about why this question belongs in an article about peptides. It is not a technicality I am reaching for. Every other question on this page asks you to evaluate a clinic's claims. This one asks whether the clinic has quietly removed your ability to evaluate it at all — and by extension, whether the reviews you read before choosing them were ever a real sample. A five-star average assembled under a pre-approval requirement is not evidence about the medicine. It is evidence about the contract.
What we do instead: Limitless will never ask you to clear a review with us, in either direction. No non-disparagement clause, no review-approval provision, and no pre-publication consent requirement appears in any Limitless patient agreement. If your experience here is bad, say so publicly, and I would rather read it in the open where I can answer it.
A seventh question, and in Georgia it is a corporate structure question.
I added this one on 2026-08-19. Every question above asks who treats you. This one asks who owns the room — and in Georgia that is not a philosophical distinction, it is a doctrine with a name.
"Who owns this practice — a physician, or a management company?"
Georgia follows the corporate practice of medicine doctrine. The short version: a lay corporation may not practice medicine, employ physicians to practice medicine on its behalf, or control physicians' medical judgment. The clinical entity is meant to be owned by licensed practitioners.
The structure built to work around this is the MSO — a management services organization. A non-physician entity owns the brand, the lease, the marketing, the equipment, the staff contracts, and the revenue; a physician-owned professional corporation exists on paper to hold the license. Done carefully and honestly, an MSO is lawful and common. Done the way it is often done in this industry, the physician whose name is on the entity has no meaningful control over what the practice does, is paid a flat monthly fee, and has never set foot in the building.
That is the arrangement the Georgia Composite Medical Board's May 7, 2026 position statement targets from the other direction. The Board bars a physician from being financially dependent on the APRN they supervise, and expressly names third-party medical-director matching services — the businesses that exist to connect a clinic that needs a signature with a physician willing to sell one. Pair that with the unannounced inspections the Board began this summer, which reportedly found practices operating with no physician oversight at all, and the ownership question stops being abstract.
What a good answer sounds like"Dr. [name] owns it. Here is the entity, here is the license number, look it up." — and the name they give you is the same name on the protocols, the prescriptions, and the door.
"We're part of the [brand] family." "We have a national medical board." "Our medical director is Dr. [name]" — where that physician does not practice in your state, or supervises dozens of locations, or cannot be produced.
The tell is usually the franchise page. A brand with twenty locations across six states has one physician-owner per state at most, and frequently none. Ask which entity is billing you, and who owns it. You are entitled to know who is financially responsible for your care.
I want to be careful here, because this is the question on which I am least neutral. Limitless is physician-owned, so the answer flatters us, and you should discount for that. So let me put the argument in a form that does not depend on my situation: ownership determines what happens when medicine and margin disagree. If the entity that decides your protocol also owns the inventory and answers to investors, that conflict gets resolved somewhere, by someone. Asking who owns the practice tells you where.
What we do instead: Limitless Performance Medicine is owned and operated by Joshua Hare, DO. There is no management company, no franchisor, no private-equity sponsor, no rented medical director, and no matching service. The physician who writes your protocol is the physician who owns the practice and carries the license it operates under. If that ever changes, this page will say so.
The question underneath all seven: who is actually treating you?
Read a clinic's marketing and its staffing page side by side. They are frequently describing different practices.
A model I now see repeatedly in Georgia and Tennessee: the brand is founded by someone who is not a physician — a chiropractor, most often, sometimes an entrepreneur with no clinical license at all. Prescriptions are written by a nurse practitioner. A physician is named as medical director, providing oversight. And the marketing describes the whole arrangement as "physician-guided."
I want to be precise, because this is where it would be easy to be unfair. Nurse practitioners are excellent clinicians, and in Georgia and Tennessee an NP prescribing under a proper collaborative arrangement is practicing entirely lawfully. This is not an argument that NP-delivered care is bad care. Some of the best clinicians I have worked with are nurse practitioners.
Update, August 2026: this stopped being purely a marketing question this summer. The Georgia Composite Medical Board began unannounced inspections of med spas and IV clinics, and reporting on what inspectors found includes chiropractors offering testosterone and weight-loss treatments — which Georgia's chiropractic scope statute does not authorize. The Board's May 7 IV therapy position statement separately prohibits generic standing orders, requires a prescriber-completed history and physical before anything is compounded, and bars a physician from being financially dependent on the APRN they delegate to. Georgia has, in effect, turned "who is actually in charge here" into a licensure question with inspectors attached. We wrote the license-by-license version: Who is allowed to inject you?
The issue is the gap between the arrangement and the impression. "Physician-guided" and "physician-led" sound like the same phrase and describe different things. In one, a physician reviews protocols and is available for consultation. In the other, a physician reads your labs, chooses your therapy, and signs your prescription. Both can be good care. Only one is what most patients think they are buying when they see a doctor's photograph on the homepage.
Ask it plainly. All four have different answers.
- Who reads my labs — line by line, and against what ranges?
- Who designs my protocol?
- Who signs the prescription?
- Does the physician named as medical director personally review my case, or supervise the practice in general?
At Limitless the answer to all four is the same person, and you can see him. That is the entire reason the practice is structured the way it is.
Why the claims matter more than the substances.
A point I keep returning to, because it is the part most clinics have not absorbed: the July hearing made aggressive marketing more dangerous, not less.
Unqualified safety and efficacy claims about non-FDA-approved compounded products have always carried exposure under the prescription drug advertising rules at 21 CFR 202 and under the FTC Act, which requires competent and reliable scientific evidence behind a health claim. What changed in July is that the federal record now documents the absence of that evidence, substance by substance, in briefing materials prepared for a public advisory committee. A clinic asserting that a peptide is "incredibly safe," "clinically proven," or simply "safe — yes" is now making a claim contradicted by a published federal assessment.
This is not hypothetical. FDA issued 30 warning letters in a single day in March 2026 and more than 80 to telehealth companies over the past year, and overwhelmingly those letters were about what the advertising said — not about the clinical judgment behind any individual prescription.
Which produces the counterintuitive result at the center of this article: the clinic making the boldest safety claims is usually the one that has read the least.
What this looks like here.
I read every lab personally. I write every protocol. I sign every prescription. When a substance is not lawful to compound, we do not carry it — CJC-1295 is the clearest example, and we use tesamorelin, an FDA-approved GHRH analog with randomized CT-measured outcome data, instead. When the evidence is thin, the consent form says so in plain language rather than burying it. When we get something wrong, we correct it in public with the date attached.
And we keep a dated tracker of the entire regulatory process — including the parts that cut against our own interests — so that any patient can check whether we are still current. That is the standard I am asking you to hold every clinic to, including this one.
If you are evaluating peptide therapy anywhere in North Georgia, Chattanooga, or East Tennessee, take these six questions with you. Ask them here too — and if you do not like the answers you get from me, the sixth question guarantees you can say so.